ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0385

Cross-cultural Validation of the “Effects of Youngsters-Eyesight on Quality of Life (EYE-Q)”: A Measure of Vision-related Quality of Life and Function in Childhood Uveitis

sheila Angeles-Han1, Jordi Anton2, Amra Adrovic3, Patricia Costa Reis4, Joke De Boer5, Séverine Guillaume-Czitrom6, Theresa Hennard7, Marija Jelusic8, Ozgur Kasapcopur9, Ilaria Maccora10, Hana Malcova11, Joseph McDonald12, Najima Mwase13, Gabriele Simonini14, Waheba Slamang15, Derrik du Toit16, Hendrike van Vollenhoven16 and Ivan Foeldvari17, 1Cincinnati Children's Hospital, Cincinnati, OH, 2Hospital Sant Joan de Déu. Universitat de Barcelona, Esplugues de Llobregat (Barcelona), Spain, 3Deparment of Pediatric Rheumatology, Istanbul University-Cerrahpasa, Istanbul, Turkey, 4Hospital de Santa Maria, Lisbon, Portugal, 5Department of ophthalmology, University Medical Center Utrecht, Utrecht, Netherlands, 6University Hospital of Bicetre, Kremlin-Bicêtre, France, 7Cincinnati Children's Hospital and Medical Center, Cincinnati, OH, 8University of Zagreb School of Medicine, University Hospital Centre Zagreb, Zagreb, Zagreb, Croatia, 9Istanbul University-Cerrahpasa, Cerrahpasa Medical School, istanbul, Turkey, 10?PhD student, in the Area of Drugs and Innovative Treatments, NeuroFARBA Department, University of Florence. Meyer Children's Hospital, Florence Italy, Firenze, Florence, Italy, 11FN Motol, Praha, Czech Republic, 12University of Chicago, Chicago, IL, 13Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 14Meyer Children Hospital IRCCS; NEUROFARBA Department, University of Florence, Florence, Italy, 15University of Cape Town, Department of Child and Adolescent Health, Cape Town, South Africa, 16Red Cross Children’s Hospital, Cape Town, South Africa, 17Hamburg Centre for Pediatric and Adolescence Rheumatology, Hamburg, Germany

Meeting: ACR Convergence 2024

Keywords: Eye Disorders, Juvenile idiopathic arthritis, Outcome measures, Pediatric rheumatology, quality of life

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 16, 2024

Title: Pediatric Rheumatology – Clinical Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose:

Childhood uveitis leads to sight-threatening complications in 50% of affected children and significantly impacts a child’s quality of life and function. The Multinational Interdisciplinary Working Group for Uveitis (MIWGUC) group developed outcome measures to assess pediatric uveitis, but a uveitis-specific quality patient reported outcome measure (PRO) was lacking. The Effects of Youngsters’ Eyesight on Quality of Life (EYE-Q) is the first and only validated instrument that measures vision-related quality of life and function in childhood uveitis. The EYE-Q is an easily administered, child-centered questionnaire validated in multicenter studies of >500 children in the United States. The EYE-Q was only available in the US English language. Our aim is to conduct a cross-cultural adaptation and pre-pilot testing of the EYE-Q in several languages to expand its use for global uveitis studies.

Methods: Methods were adapted from Guillemin et. al (1993, J Clin Epidemiol 46:1417–1432), similar to the CHAQ, JAMAR and CHQ – 1) Phase I: Cross-cultural adaptation and 2) Phase II: Pre-pilot testing probe (Figure 1). For Phase I, to develop the first unified version of the EYE-Q in the national language, three medical translators well-versed in American English completed a forward translation of the American English EYE-Q to the National Language.  Three other medical translators then created a unified backtranslation to American English. The unified backtranslation of the EYE-Q was reviewed by the US team that developed the EYE-Q. They confirmed the relevance and comprehensibility of the items by parents and children and verified the cross-cultural equivalence versions by comparing their semantic, idiomatic, experiential and conceptual equivalencies. A second unified version of the EYE-Q was developed by the national language incorporating comments received to achieve consensus. The US team reviewed and either approved or provided additional feedback for a third review.

For Phase II, we pre-tested the second unified version of the EYE-Q in the National Language. The EYE-Q was administered to 10 children and parents to test comprehensibility and relevance of the items in each country. Each item of the translated EYE-Q had to be understood by at least 80%; items misunderstood by 20% or more of the parents or children would be reviewed and revised appropriately. If changes to the items were needed after the interviews, another round of forward and backward translations were required. This third unified version was then developed for a future Phase III Validation study.

Results: We completed forward and backward translations and developed a unified version of the EYE-Q in the following nine National languages that has undergone pre-pilot testing: Afrikaans, Croatian, Dutch, French, German, Italian, Portuguese (Portugal), Spanish (Spain) and Turkish. We are still in process of developing a unified version for Portuguese (Brazil), UK English, and Czech.

Conclusion: Cross-culturally adapted versions of the EYE-Q in several national languages have been developed. These will undergo validation in a prospective MIWGUC project to assess the correlation with other already proposed outcome measures of childhood uveitis.

Supporting image 1

Figure 1. Process for Cross-Cultural Validation of the EYE-Q – Phases I and II Completed


Disclosures: s. Angeles-Han: None; J. Anton: None; A. Adrovic: None; P. Costa Reis: None; J. Boer: None; S. Guillaume-Czitrom: None; T. Hennard: None; M. Jelusic: None; O. Kasapcopur: None; I. Maccora: None; H. Malcova: None; J. McDonald: None; N. Mwase: None; G. Simonini: None; W. Slamang: None; D. Toit: None; H. Vollenhoven: None; I. Foeldvari: None.

To cite this abstract in AMA style:

Angeles-Han s, Anton J, Adrovic A, Costa Reis P, Boer J, Guillaume-Czitrom S, Hennard T, Jelusic M, Kasapcopur O, Maccora I, Malcova H, McDonald J, Mwase N, Simonini G, Slamang W, Toit D, Vollenhoven H, Foeldvari I. Cross-cultural Validation of the “Effects of Youngsters-Eyesight on Quality of Life (EYE-Q)”: A Measure of Vision-related Quality of Life and Function in Childhood Uveitis [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/cross-cultural-validation-of-the-effects-of-youngsters-eyesight-on-quality-of-life-eye-q-a-measure-of-vision-related-quality-of-life-and-function-in-childhood-uveitis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cross-cultural-validation-of-the-effects-of-youngsters-eyesight-on-quality-of-life-eye-q-a-measure-of-vision-related-quality-of-life-and-function-in-childhood-uveitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology